<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ssmu</journal-id><journal-title-group><journal-title xml:lang="ru">Бюллетень сибирской медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of Siberian Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-0363</issn><issn pub-type="epub">1819-3684</issn><publisher><publisher-name>Siberian State Medical University, the Ministry of Healthcare of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20538/1682-0363-2022-4-88-97</article-id><article-id custom-type="elpub" pub-id-type="custom">ssmu-5028</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>Сердечная недостаточность с сохраненной фракцией выброса: роль микроваскулярной дисфункции</article-title><trans-title-group xml:lang="en"><trans-title>Heart failure with preserved ejection fraction: the role of microvascular dysfunction</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2285-6438</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Копьева</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kopeva</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Копьева Кристина Васильевна – кандидат медицинских наук, науч. сотрудник, отделение патологии миокарда</p><p>634012, Томск, ул. Киевская, 111а</p><p> </p></bio><bio xml:lang="en"><p>111а, Kievskaya Str., Tomsk, 634012</p></bio><email xlink:type="simple">Kristin-kop@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1311-0378</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мочула</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mochula</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мочула Андрей Викторович – кандидат медицинских наук, старший науч. сотрудник, лаборатория радионуклидных методов исследования</p><p>634012, Томск, ул. Киевская, 111а</p><p> </p></bio><bio xml:lang="en"><p>111а, Kievskaya Str., Tomsk, 634012</p></bio><email xlink:type="simple">maltseva.alina.93@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1311-0378</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мальцева</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Maltseva</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мальцева Алина Николаевна – аспирант, лаборатория радионуклидных методов исследования</p><p>634012, Томск, ул. Киевская, 111а</p></bio><bio xml:lang="en"><p>111а, Kievskaya Str., Tomsk, 634012</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4019-3735</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гракова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Grakova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гракова Елена Викторовна – доктор медицинских наук, вед. науч. сотрудник, отделение патологии миокарда</p><p>634012, Томск, ул. Киевская, 111а</p><p> </p></bio><bio xml:lang="en"><p>111а, Kievskaya Str., Tomsk, 634012</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9887-8214</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шипулин</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shipulin</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шипулин Владимир Владимирович – кандидат медицинских наук, мл. науч. сотрудник, лаборатория радионуклидных методов исследования</p><p>634012, Томск, ул. Киевская, 111а</p></bio><bio xml:lang="en"><p>111а, Kievskaya Str., Tomsk, 634012</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0883-466X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гусакова</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Gusakova</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гусакова Анна Михайловна – кандидат биологических наук, науч. сотрудник клинической лабораторной диагностики</p><p>634012, Томск, ул. Киевская, 111а</p></bio><bio xml:lang="en"><p>111а, Kievskaya Str., Tomsk, 634012</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1513-8614</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Завадовский</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zavadovsky</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Завадовский Константин Валерьевич – доктор медицинских наук, зав. лабораторией радионуклидных методов исследования</p><p>634012, Томск, ул. Киевская, 111а</p></bio><bio xml:lang="en"><p>111а, Kievskaya Str., Tomsk, 634012</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт (НИИ) кардиологии, Томский национальный исследовательский медицинский центр (НИМЦ) Российской академии наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Cardiology Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>21</day><month>01</month><year>2023</year></pub-date><volume>21</volume><issue>4</issue><fpage>88</fpage><lpage>97</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Копьева К.В., Мочула А.В., Мальцева А.Н., Гракова Е.В., Шипулин В.В., Гусакова А.М., Завадовский К.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Копьева К.В., Мочула А.В., Мальцева А.Н., Гракова Е.В., Шипулин В.В., Гусакова А.М., Завадовский К.В.</copyright-holder><copyright-holder xml:lang="en">Kopeva K.V., Mochula A.V., Maltseva A.N., Grakova E.V., Shipulin V.V., Gusakova A.M., Zavadovsky K.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://bulletin.ssmu.ru/jour/article/view/5028">https://bulletin.ssmu.ru/jour/article/view/5028</self-uri><abstract><sec><title>Цель</title><p>Цель. Оценить взаимосвязь между коронарной микроваскулярной дисфункцией (КМД), биомаркерами фиброза и миокардиального ремоделирования (растворимый ST2 (sST2) и фактор роста фибробластов 23 (FGF-23), матриксная металлопротеиназа-9 (ММП-9), тканевой ингибитор металлопротеиназ-1 (ТИМП-1), NT-proBNP), параметрами диастолической дисфункции (ДД) и наличием сердечной недостаточности с сохраненной фракцией (СНсФВ) у симптоматичных пациентов.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование включены 59 пациентов с необструктивным поражением коронарных артерий (КА) и сохраненной фракцией выброса левого желудочка (ФВ ЛЖ) 62 (56; 67)%. Необструктивное поражение КА было подтверждено компьютерной коронарной ангиографией. С помощью динамической CZT-SRECT оценивали параметры миокардиального кровотока в состоянии покоя (rest-MBF) и стресса (stress-MFR) и резерва коронарного кровотока (CFR). Сывороточные уровни сердечных биомаркеров измеряли с помощью иммуноферментного анализа. Всем пациентам проводилась двухмерная трансторакальная эхокардиография для оценки параметров ДД.</p></sec><sec><title>Результаты</title><p>Результаты. Сниженный CFR определяли как CFR ≤2. Таким образом, КМД диагностировали на основании сниженного CFR при отсутствии окклюзирующего поражения КА. Распределение пациентов проводилось по значениям CFR: группа 1 включала больных с сохраненным CFR (&gt;2, n = 35), группа 2 – со сниженным CFR (≤2, n = 24). В 87,5% случаев у больных с КМД была диагностирована СНсФВ, тогда как у больных без КМД – только в 51,4% (р &lt; 0,0001). Значения CFR коррелировали с объемом левого предсердия (r = –0,527; p = 0,001), отношением E/A (r = –0,321; p = 0,012) и E/e’ (r = –0,307; p = 0,021). На основании ROC-анализа уровни sST2 ≥ 31,304 нг/мл (AUС = 0,730; р = 0,004) и NT-proBNP ≥ 0,034 пг/мл (AUС = 0,815; р = 0,034) были определены как пороговые значения для диагностики КМД у пациентов с необструктивным поражением КА.</p></sec><sec><title>Заключение</title><p>Заключение. КМД может играть важную роль в патогенезе развития СНсФВ. Значения CFR коррелировали с параметрами ДД, а снижение CFR было связано с гиперэкспрессией сердечных биомаркеров фиброза и ремоделирования. Уровни sST2 и NT-proBNP могут использоваться в качестве маркеров неинвазивной диагностики КМД.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To evaluate the relationship between coronary microvascular dysfunction (CMD), biomarkers of cardiac fibrosis and cardiac remodeling (soluble ST2 (sST2), fibroblast growth factor-23 (FGF-23), matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), and NT-proBNP), parameters of diastolic dysfunction (DD), and the presence of heart failure with preserved ejection fraction (HFpEF) in symptomatic patients.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Study participants were 59 patients with non-obstructive coronary artery disease (CAD) and preserved left ventricular ejection fraction (LVEF) of 62 (56; 67) %. Non-obstructive CAD was verified by coronary computed tomography angiography. Stress-and rest-myocardial blood flow (MBF) and coronary flow reserve (CFR) parameters were evaluated by CZT SPECT. Serum levels of cardiac biomarkers were measured by the enzyme immunoassay. Two-dimensional transthoracic echocardiography was used to assess DD parameters.</p></sec><sec><title>Results</title><p>Results. Decreased CFR was defined as CFR ≤ 2. Therefore, CMD was defined as the presence of decreased CFR in the absence of flow-limiting CAD. Distribution of patients was performed by CFR values: group 1 included patients with preserved CFR (&gt;2, n = 35), and group 2 encompassed patients with decreased CFR (≤2, n = 24). In 87.5% of cases, patients with CMD were diagnosed with HFpEF, whereas in patients with preserved CFR, heart failure was diagnosed only in 51.4% of cases (p &lt; 0.0001). CFR values were correlated with the left atrial volume (r = –0.527; p = 0.001), E / A ratio (r = –0.321, p = 0.012), and E / e’ (r = –0.307; p = 0.021). Following the ROC analysis, the levels of sST2 ≥ 31.304 ng / ml (AUС = 0.730; р = 0.004) and NT-proBNP ≥ 0.034 pg / ml (AUС = 0.815; р = 0.034) were identified as cut-off values for the presence of CMD in patients with non-obstructive CAD.</p></sec><sec><title>Conclusion</title><p>Conclusion. The obtained data suggest that CMD may play an essential role in HFpEF. The values of CFR were correlated with DD parameters, and decreased CFR was associated with overexpression of biomarkers of cardiac fibrosis and cardiac remodeling. Serum levels of sST2 and NT-proBNP were identified as cut-off values for the presence of CMD in patients with non-obstructive CAD.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сердечная недостаточность</kwd><kwd>сохраненная фракция выброса левого желудочка</kwd><kwd>диастолическая дисфункция</kwd><kwd>коронарный резерв</kwd><kwd>миокардиальный кровоток</kwd><kwd>микрососудистая дисфункция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>heart failure</kwd><kwd>preserved left ventricular ejection fraction</kwd><kwd>diastolic dysfunction</kwd><kwd>coronary flow reserve</kwd><kwd>myocardial blood flow</kwd><kwd>microvascular dysfunction</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование поддержано грантом президента Российской Федерации (MK-4257.2022.3).</funding-statement><funding-statement xml:lang="en">The study was supported by the grant awarded by the President of the Russian Federation MK-4257.2022.3</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G., Coats A.J. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016;18(8):891–975. DOI: 10.1002/ejhf.592.</mixed-citation><mixed-citation xml:lang="en">Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G., Coats A.J. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016;18(8):891–975. DOI: 10.1002/ejhf.592.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Groenewegen A., Rutten F.H., Mosterd A., Hoes A.W. Epidemiology of heart failure. 2020;22(8):1342–1356. DOI: 10.1002/ejhf.1858.</mixed-citation><mixed-citation xml:lang="en">Groenewegen A., Rutten F.H., Mosterd A., Hoes A.W. Epidemiology of heart failure. 2020;22(8):1342–1356. DOI: 10.1002/ejhf.1858.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">McDonagh T.A., Metra M., Adamo M., Gardner R.S. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2021;42(36): 3599–3726. DOI: 10.1093/eurheartj/ehab368.</mixed-citation><mixed-citation xml:lang="en">McDonagh T.A., Metra M., Adamo M., Gardner R.S. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2021;42(36): 3599–3726. DOI: 10.1093/eurheartj/ehab368.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Tona F., Montisci R., Iop L., Civieri G. Role of coronary microvascular dysfunction in heart failure with preserved ejection fraction. Rev. Cardiovasc. Med. 2021;22(1):97–104. DOI: 10.31083/j.rcm.2021.01.277.</mixed-citation><mixed-citation xml:lang="en">Tona F., Montisci R., Iop L., Civieri G. Role of coronary microvascular dysfunction in heart failure with preserved ejection fraction. Rev. Cardiovasc. Med. 2021;22(1):97–104. DOI: 10.31083/j.rcm.2021.01.277.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Vancheri F., Longo G., Vancheri S., Henein M. Coronary microvascular dysfunction. J. Clin. Med. 2020;9(9):2880. DOI: 10.3390/jcm9092880.</mixed-citation><mixed-citation xml:lang="en">Vancheri F., Longo G., Vancheri S., Henein M. Coronary microvascular dysfunction. J. Clin. Med. 2020;9(9):2880. DOI: 10.3390/jcm9092880.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Crea F., Bairey Merz C.N., Beltrame J.F., Kaski J.C. et al. The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift. Eur. Heart J. 2017;38(7):473–477. DOI: 10.1093/eurheartj/ehw461.</mixed-citation><mixed-citation xml:lang="en">Crea F., Bairey Merz C.N., Beltrame J.F., Kaski J.C. et al. The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift. Eur. Heart J. 2017;38(7):473–477. DOI: 10.1093/eurheartj/ehw461.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Taqueti V.R., Solomon S.D., Shah A.M., Desai A.S. et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur. Heart J. 2018;39(10):840–849. DOI: 10.1093/eurheartj/ehx721.</mixed-citation><mixed-citation xml:lang="en">Taqueti V.R., Solomon S.D., Shah A.M., Desai A.S. et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur. Heart J. 2018;39(10):840–849. DOI: 10.1093/eurheartj/ehx721.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Rahman H., Scannell C.M., Demir O.M., Ryan M. et al. High-resolution сardiac magnetic resonance imaging techniques for the identification of coronary microvascular dysfunction. JACC Cardiovasc. Imaging. 2021 14(5):978–986. DOI: 10.1016/j.jcmg.2020.10.015.</mixed-citation><mixed-citation xml:lang="en">Rahman H., Scannell C.M., Demir O.M., Ryan M. et al. High-resolution сardiac magnetic resonance imaging techniques for the identification of coronary microvascular dysfunction. JACC Cardiovasc. Imaging. 2021 14(5):978–986. DOI: 10.1016/j.jcmg.2020.10.015.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zavadovsky K.V., Mochula A.V., Boshchenko A.A. et al. Absolute myocardial blood flows derived by dynamic CZT scan vs invasive fractional flow reserve: Correlation and accuracy. J. Nucl. Cardiol. 2021;28(1):249–259. DOI: 10.1007/s12350019-01678-z.;</mixed-citation><mixed-citation xml:lang="en">Zavadovsky K.V., Mochula A.V., Boshchenko A.A. et al. Absolute myocardial blood flows derived by dynamic CZT scan vs invasive fractional flow reserve: Correlation and accuracy. J. Nucl. Cardiol. 2021;28(1):249–259. DOI: 10.1007/s12350019-01678-z.;</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zavadovsky K.V., Mochula A.V., Maltseva A.N., Boshchenko A.A. et al. The diagnostic value of SPECT CZT quantitative myocardial blood flow in high-risk patients. J. Nucl. Cardiol. 2022; 29(3):1051–1063. DOI: 10.1007/s12350-02002395-8.</mixed-citation><mixed-citation xml:lang="en">Zavadovsky K.V., Mochula A.V., Maltseva A.N., Boshchenko A.A. et al. The diagnostic value of SPECT CZT quantitative myocardial blood flow in high-risk patients. J. Nucl. Cardiol. 2022; 29(3):1051–1063. DOI: 10.1007/s12350-02002395-8.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Murthy V.L., Naya M., Foster C.R., Hainer J. et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation. 2011;124(20):2215–2224. DOI: 10.1161/CIRCULATIONAHA.111.050427.</mixed-citation><mixed-citation xml:lang="en">Murthy V.L., Naya M., Foster C.R., Hainer J. et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation. 2011;124(20):2215–2224. DOI: 10.1161/CIRCULATIONAHA.111.050427.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Agostini D., Roule V., Nganoa C. et al. First validation of myocardial flow reserve assessed by dynamic 99mTc-sestamibi CZT-SPECT camera: head to head comparison with 15O-water PET and fractional flow reserve in patients with suspected coronary artery disease. The WATERDAY study. Eur. J. Nucl. Med. Mol. Imaging. 2018;45(7):1079–1090. DOI: 10.1007/s00259-018-3958-7.</mixed-citation><mixed-citation xml:lang="en">Agostini D., Roule V., Nganoa C. et al. First validation of myocardial flow reserve assessed by dynamic 99mTc-sestamibi CZT-SPECT camera: head to head comparison with 15O-water PET and fractional flow reserve in patients with suspected coronary artery disease. The WATERDAY study. Eur. J. Nucl. Med. Mol. Imaging. 2018;45(7):1079–1090. DOI: 10.1007/s00259-018-3958-7.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Paulus W.J., Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 2013;62(4):263–271. DOI: 10.1016/j.jacc.2013.02.092.</mixed-citation><mixed-citation xml:lang="en">Paulus W.J., Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 2013;62(4):263–271. DOI: 10.1016/j.jacc.2013.02.092.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Godo S., Suda A., Takahashi J., Yasuda S., Shimokawa H. Coronary microvascular dysfunction. Arteriosclerosis, Thrombosis, and Vascular Biology. 2021;41(5):1625–1637. DOI: 10.1161/ATVBAHA.121.316025.</mixed-citation><mixed-citation xml:lang="en">Godo S., Suda A., Takahashi J., Yasuda S., Shimokawa H. Coronary microvascular dysfunction. Arteriosclerosis, Thrombosis, and Vascular Biology. 2021;41(5):1625–1637. DOI: 10.1161/ATVBAHA.121.316025.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mileva N., Nagumo S., Mizukami T., Sonck J. et al. Prevalence of Coronary Microvascular Disease and Coronary Vasospasm in Patients With Nonobstructive Coronary Artery Disease: Systematic Review and Meta-Analysis. J. Amer. Heart Ass. 2022;11(7):e023207. DOI: 10.1161/JAHA.121.023207.</mixed-citation><mixed-citation xml:lang="en">Mileva N., Nagumo S., Mizukami T., Sonck J. et al. Prevalence of Coronary Microvascular Disease and Coronary Vasospasm in Patients With Nonobstructive Coronary Artery Disease: Systematic Review and Meta-Analysis. J. Amer. Heart Ass. 2022;11(7):e023207. DOI: 10.1161/JAHA.121.023207.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou H., Toan S. Pathological roles of mitochondrial oxidative stress and mitochondrial dynamics in cardiac microvascular ischemia/reperfusion injury. Biomolecules. 2020;10(1):85. DOI: 10.3390/biom10010085.</mixed-citation><mixed-citation xml:lang="en">Zhou H., Toan S. Pathological roles of mitochondrial oxidative stress and mitochondrial dynamics in cardiac microvascular ischemia/reperfusion injury. Biomolecules. 2020;10(1):85. DOI: 10.3390/biom10010085.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Nagueh S.F., Smiseth O.A., Appleton C.P. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging. 2016;17(12):1321–1360. DOI: 10.1093/ehjci/jew082.</mixed-citation><mixed-citation xml:lang="en">Nagueh S.F., Smiseth O.A., Appleton C.P. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging. 2016;17(12):1321–1360. DOI: 10.1093/ehjci/jew082.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Henzlova M.J., Duvall W.L., Einstein A.J., Travin M.I., Verberne H.J. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J. Nucl. Cardiol. 2016;23 (3):606–639. DOI: 10.1007/s12350-0150387-x.</mixed-citation><mixed-citation xml:lang="en">Henzlova M.J., Duvall W.L., Einstein A.J., Travin M.I., Verberne H.J. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J. Nucl. Cardiol. 2016;23 (3):606–639. DOI: 10.1007/s12350-0150387-x.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Leppo J.A., Meerdink D.J. Comparison of the myocardial uptake of a technetium-labeled isonitrile analogue and thallium. Circ. Res. 1989;65(3):632–639. DOI: 10.1161/01.res.65.3.632.</mixed-citation><mixed-citation xml:lang="en">Leppo J.A., Meerdink D.J. Comparison of the myocardial uptake of a technetium-labeled isonitrile analogue and thallium. Circ. Res. 1989;65(3):632–639. DOI: 10.1161/01.res.65.3.632.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Cerqueira M.D., Weissman N.J., Dilsizian V., Jacobs A.K. et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the cardiac imaging. Circulation. 2002;105(4):539–542. DOI: 10.1161/hc0402.102975.</mixed-citation><mixed-citation xml:lang="en">Cerqueira M.D., Weissman N.J., Dilsizian V., Jacobs A.K. et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the cardiac imaging. Circulation. 2002;105(4):539–542. DOI: 10.1161/hc0402.102975.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Austen W.G., Edwards J.E., Frye R.L., Gensini G.G. et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975;51(4):5–40. DOI: 10.1161/01.cir.51.4.5.</mixed-citation><mixed-citation xml:lang="en">Austen W.G., Edwards J.E., Frye R.L., Gensini G.G. et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975;51(4):5–40. DOI: 10.1161/01.cir.51.4.5.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Clark K.A.A., Velazquez E.J. Heart failure with preserved ejection fraction: time for a Reset. JAMA. 2020;324(15):1506– 1508. DOI: 10.1001/jama.2020.15566.</mixed-citation><mixed-citation xml:lang="en">Clark K.A.A., Velazquez E.J. Heart failure with preserved ejection fraction: time for a Reset. JAMA. 2020;324(15):1506– 1508. DOI: 10.1001/jama.2020.15566.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Triposkiadis F., Butler J., Abboud F.M., Armstrong P.W., Adamopoulos S., Atherton J.J. et al. The continuous heart failure spectrum: moving beyond an ejection fraction classification. Eur. Heart J. 2019;40(26):2155–2163. DOI: 10.1093/eurheartj/ehz158.</mixed-citation><mixed-citation xml:lang="en">Triposkiadis F., Butler J., Abboud F.M., Armstrong P.W., Adamopoulos S., Atherton J.J. et al. The continuous heart failure spectrum: moving beyond an ejection fraction classification. Eur. Heart J. 2019;40(26):2155–2163. DOI: 10.1093/eurheartj/ehz158.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Graziani F., Varone F., Crea F., Richeldi L. Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis. Eur. J. Heart Fail. 2018;20(10):1385–1391. DOI: 10.1002/ejhf.1286.</mixed-citation><mixed-citation xml:lang="en">Graziani F., Varone F., Crea F., Richeldi L. Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis. Eur. J. Heart Fail. 2018;20(10):1385–1391. DOI: 10.1002/ejhf.1286.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Zile M.R., Baicu C.F., Ikonomidis J.S., Stroud R.E., Nietert P.J. et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131(14):1247–1259. DOI: 10.1161/CIRCULATIONAHA.114.013215.</mixed-citation><mixed-citation xml:lang="en">Zile M.R., Baicu C.F., Ikonomidis J.S., Stroud R.E., Nietert P.J. et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131(14):1247–1259. DOI: 10.1161/CIRCULATIONAHA.114.013215.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Rahman H., Ryan M., Lumley M., Modi B. et al. Coronary microvascular dysfunction is associated with myocardial ischemia and abnormal coronary perfusion during exercise. Circulation. 2019;140:1805–1816. DOI: 10.1161/CIRCULATIONAHA.119.041595.</mixed-citation><mixed-citation xml:lang="en">Rahman H., Ryan M., Lumley M., Modi B. et al. Coronary microvascular dysfunction is associated with myocardial ischemia and abnormal coronary perfusion during exercise. Circulation. 2019;140:1805–1816. DOI: 10.1161/CIRCULATIONAHA.119.041595.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kim I.C., Hwang J., Lee C.H., Cho Y.K. et al. Correlation of coronary microvascular function and diastolic dysfunction. Eur. Heart J. 2020;41(2):ehaa946.0903. DOI: 10.1093/ehjci/ehaa946.0903.</mixed-citation><mixed-citation xml:lang="en">Kim I.C., Hwang J., Lee C.H., Cho Y.K. et al. Correlation of coronary microvascular function and diastolic dysfunction. Eur. Heart J. 2020;41(2):ehaa946.0903. DOI: 10.1093/ehjci/ehaa946.0903.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Snoer M., Monk-Hansen T., Olsen R.H., Pedersen L.R., Nielsen O.W. et al. Coronary flow reserve as a link between diastolic and systolic function and exercise capacity in heart failure. Eur. Heart J. Cardiovasc. Imaging. 2013;14(7):677–683. DOI: 10.1093/ehjci/jes269.</mixed-citation><mixed-citation xml:lang="en">Snoer M., Monk-Hansen T., Olsen R.H., Pedersen L.R., Nielsen O.W. et al. Coronary flow reserve as a link between diastolic and systolic function and exercise capacity in heart failure. Eur. Heart J. Cardiovasc. Imaging. 2013;14(7):677–683. DOI: 10.1093/ehjci/jes269.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Garbern J.C., Williams J., Kristl A.C., Malick A., Rachmin I. et al. Dysregulation of IL-33/ST2 signaling and myocardial periarteriolar fibrosis. J. Mol. Cell Cardiol. 2019;128:179– 186. DOI: 10.1016/j.yjmcc.2019.01.018.</mixed-citation><mixed-citation xml:lang="en">Garbern J.C., Williams J., Kristl A.C., Malick A., Rachmin I. et al. Dysregulation of IL-33/ST2 signaling and myocardial periarteriolar fibrosis. J. Mol. Cell Cardiol. 2019;128:179– 186. DOI: 10.1016/j.yjmcc.2019.01.018.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis G.A., Schelbert E.B., Williams S.G., Cunnington C., Ahmed F., McDonagh T.A. et al. Biological phenotypes of heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 2017;70(17):2186–2200. DOI: 10.1016/j.jacc.2017.09.006.</mixed-citation><mixed-citation xml:lang="en">Lewis G.A., Schelbert E.B., Williams S.G., Cunnington C., Ahmed F., McDonagh T.A. et al. Biological phenotypes of heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 2017;70(17):2186–2200. DOI: 10.1016/j.jacc.2017.09.006.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Aslan G., Polat V., Bozcali E., Opan S., Çetin N., Ural D. Evaluation of serum sST2 and sCD40L values in patients with microvascular angina. Microvasc. Res. 2019;122:85–93. DOI: 10.1016/j.mvr.2018.11.009.</mixed-citation><mixed-citation xml:lang="en">Aslan G., Polat V., Bozcali E., Opan S., Çetin N., Ural D. Evaluation of serum sST2 and sCD40L values in patients with microvascular angina. Microvasc. Res. 2019;122:85–93. DOI: 10.1016/j.mvr.2018.11.009.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Гракова Е.В., Копьева К.В., Тепляков А.Т., Oгуркова O.Н., Солдатенко М.В., Гарганеева А.А. Возможности клинического применения нового биомаркера ST2 у больных с хронической сердечной недостаточностью ишемического генеза: тест с физической нагрузкой. Кардиоваскулярная тераnия и nрофилактика. 2019;18(4):12–18. DOI: 10.15829/1728-8800-2019-4-12-18.</mixed-citation><mixed-citation xml:lang="en">Гракова Е.В., Копьева К.В., Тепляков А.Т., Oгуркова O.Н., Солдатенко М.В., Гарганеева А.А. Возможности клинического применения нового биомаркера ST2 у больных с хронической сердечной недостаточностью ишемического генеза: тест с физической нагрузкой. Кардиоваскулярная тераnия и nрофилактика. 2019;18(4):12–18. DOI: 10.15829/1728-8800-2019-4-12-18.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
